TY - JOUR
T1 - Single-dose intraoperative radiotherapy during lumpectomy for breast cancer
T2 - an innovative patient-centred treatment
AU - Vaidya, Jayant S.
AU - Bulsara, Max
AU - Baum, Michael
AU - Tobias, Jeffrey S.
AU - Wenz, Frederik
AU - Massarut, Samuele
AU - Pigorsch, Steffi
AU - Alvarado, Michael
AU - Douek, Michael
AU - Saunders, Christobel
AU - Flyger, Henrik L.
AU - Eiermann, Wolfgang
AU - Brew-Graves, Chris
AU - Williams, Norman R.
AU - Potyka, Ingrid
AU - Roberts, Nicholas
AU - Bernstein, Marcelle
AU - Brown, Douglas
AU - Sperk, Elena
AU - Laws, Siobhan
AU - Sütterlin, Marc
AU - Corica, Tammy
AU - Lundgren, Steinar
AU - Holmes, Dennis
AU - Vinante, Lorenzo
AU - Bozza, Fernando
AU - Pazos, Montserrat
AU - Le Blanc-Onfroy, Magali
AU - Gruber, Günther
AU - Polkowski, Wojciech
AU - Dedes, Konstantin J.
AU - Niewald, Marcus
AU - Blohmer, Jens
AU - McCready, David
AU - Hoefer, Richard
AU - Kelemen, Pond
AU - Petralia, Gloria
AU - Falzon, Mary
AU - Joseph, David J.
AU - on behalf of the TARGIT-A trial authors
N1 - Funding Information:
Competing interests We declare support from University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre, UCLH Charities, National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, Ninewells Cancer Campaign, National Health and Medical Research Council, and Cancer Research Campaign (now Cancer Research UK) for the submitted work; J. S.V. has received a research grant from Photoelectron Corp (1996–1999) and from Carl Zeiss for supporting data management at the University of Dundee (Dundee, UK, 2004–2008), and has received honorariums. J.S.V., J.S.T. and M.B.u. receive funding from HTA, NIHR, Department of Health and Social Care for some activities related to the TARGIT trials. M.B.a. was briefly on the scientific advisory board of Carl Zeiss and was paid consultancy fees before 2010. All authors received some travel support from Carl Zeiss. Carl Zeiss had no role in concept, design, analysis or writing of the manuscript.
Funding Information:
Funding information No specific funding was made available for this paper. The TARGIT-A trial was sponsored by University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre. Funding was provided by UCLH Charities, National Institute for Health Research (NIHR) Health Technology Assessment programme (HTA 07/60/49), Ninewells Cancer Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and Research (BMBF) FKZ 01ZP0508. The infrastructure of the trial operations office in London, UK was supported by core funding from Cancer Research Campaign (now Cancer Research UK) when the trial was initiated. The funding organisations had no role in concept, design, analysis or writing of the manuscript.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.
AB - In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.
KW - Breast Neoplasms/surgery
KW - Female
KW - Humans
KW - Intraoperative Care
KW - Mastectomy, Segmental
KW - Neoplasm Recurrence, Local
UR - http://www.scopus.com/inward/record.url?scp=85100475224&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-01233-5
DO - 10.1038/s41416-020-01233-5
M3 - Editorial
C2 - 33531693
AN - SCOPUS:85100475224
VL - 124
SP - 1469
EP - 1474
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 9
ER -